QIAGEN NV (QGEN)

32.79
0.29 0.88
NYSE : Health Technology
Prev Close 33.08
Open 33.07
Day Low/High 32.61 / 33.12
52 Wk Low/High 28.28 / 36.34
Volume 457.98K
Avg Volume 939.70K
Exchange NYSE
Shares Outstanding 226.56M
Market Cap 7.40B
EPS 0.20
P/E Ratio 194.18
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: TWNK, VIRT Downgrades: AKAM, APLE, ATVI, BHE, BRFS, CAT, CCK, CDR, CUB, DIOD, DLHC, EXPE, GRA, GT, HCN, JNPR, NWSA, QGEN, REG, SEE, SUM, SXT, TRMB, UHAL, UNVR Initiations: ICHR Read on to get TheStreet Quant Ratings' detailed report:

QIAGEN Enters Into Agreement To Acquire STAT-Dx, Plans To Launch A Next-Generation, Fully Integrated Multiplex Platform For Syndromic Disease Testing

QIAGEN Enters Into Agreement To Acquire STAT-Dx, Plans To Launch A Next-Generation, Fully Integrated Multiplex Platform For Syndromic Disease Testing

New system launch planned for second half of 2018 with two CE-IVD molecular diagnostics, U.S. launch planned for 2019 and broad pipeline in development

QIAGEN Receives FDA Clearance For First-Ever JAK2 Test For Use In Diagnosis Of Additional Myeloproliferative Neoplasms

QIAGEN Receives FDA Clearance For First-Ever JAK2 Test For Use In Diagnosis Of Additional Myeloproliferative Neoplasms

Expanded use of ipsogen test provides diagnostic testing needs for all myeloproliferative neoplasms in line with the latest WHO guidelines

QIAGEN Receives FDA Approval To Expand Use Of EGFR Test In Lung Cancer

QIAGEN Receives FDA Approval To Expand Use Of EGFR Test In Lung Cancer

Extended labeling claim adds detection of three additional gene mutations to provide the most comprehensive mutation panel for GILOTRIF®

Interesting QGEN Put And Call Options For August 2018

Interesting QGEN Put And Call Options For August 2018

Investors in Qiagen NV saw new options begin trading this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

QIAGEN And Oxford Immunotec Settle Patent Infringement Lawsuit

QIAGEN And Oxford Immunotec Settle Patent Infringement Lawsuit

Agreement includes payment of $27.5 million to Oxford, royalty free license to QIAGEN and dismissal of all pending litigation

Biomillenia Leverages QIAGEN Bioinformatics In Microbiome-on-a-Chip Discovery Of Unculturable Microbes

Biomillenia Leverages QIAGEN Bioinformatics In Microbiome-on-a-Chip Discovery Of Unculturable Microbes

Biomillenia, the developer of Smart Microbes™, announced today a collaboration with QIAGEN N.

QIAGEN Advances Precision Medicine By Automating Guidelines On Cancer Variants In Industry-leading QIAGEN Clinical Insight Software

QIAGEN Advances Precision Medicine By Automating Guidelines On Cancer Variants In Industry-leading QIAGEN Clinical Insight Software

First bioinformatics solution integrating new AMP/ASCO/CAP standards for NGS cancer testing to confidently and quickly report clinical relevance of somatic mutations

QIAGEN's GeneReader NGS System Delivers Accuracy And Ease Of Use For Clinical Research In Oncology

QIAGEN's GeneReader NGS System Delivers Accuracy And Ease Of Use For Clinical Research In Oncology

Studies at AMP 2017 demonstrate unique user experiences and high performance of new assays and workflows for multiple sample types

QIAGEN Celebrates Surpassing 2,000 Cumulative Placements Of QIAsymphony

QIAGEN Celebrates Surpassing 2,000 Cumulative Placements Of QIAsymphony

Outstanding and unmatched capabilities fuel strong growth in installed base and consumables use on highly versatile Sample to Insight automation solution

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMZN, CKH, GDDY, PRSC, QGEN, SHLM, VRX Downgrades: BRG, CZWI, FBP, HAIN, LNCE, PIH, TAIT, TPR, TTWO Initiations: ASIX, CWH Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGCO, CAL, CRS, CY, EXPE, JCI, LLNW, MITL, UPS Downgrades: AHL, BMS, EHTH, ESND, MLCO, QGEN, VGR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EFII, ENBL, NNBR, PHI, QGEN, SYX, TIER, WEX, WILC Downgrades: ADES, AEGN, ARES, CVLT, ECOM, PSX, WES Initiations: WATT Read on to get TheStreet Quant Ratings' detailed report:

Bristol-Myers Squibb And QIAGEN Sign Agreement For Use Of NGS Technology To Develop Gene Expression Profiles For Immuno-Oncology Therapies

Bristol-Myers Squibb Company (NYSE:BMY) and QIAGEN (NASDAQ:QGEN; Frankfurt Prime Standard:QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression...

TheStreet Quant Rating: C+ (Hold)